Product Overview
p53 ( internal ) peptide ( human )
Tag/Conjugate
Unconjugated
Application Notes
This product is the blocking peptide for ab2433 in Western Blot.
Buffer
Preservative: 0.1% Sodium Azide; Constituents: PBS, BSA
Preservative
0.1% Sodium Azide
Storage
Store this product at 4 °C, do not freeze. The product is stable for one year from the date of shipment.
Antigen Description
This gene encodes a tumor suppressor protein containing transcriptional activation, DNA binding, and oligomerization domains. The encoded protein responds to diverse cellular stresses to regulate expression of target genes, thereby inducing cell cycle arrest, apoptosis, senescence, DNA repair, or changes in metabolism. Mutations in this gene are associated with a variety of human cancers, including hereditary cancers such as Li-Fraumeni syndrome. Alternative splicing of this gene and the use of alternate promoters result in multiple transcript variants and isoforms. Additional isoforms have also been shown to result from the use of alternate translation initiation codons (PMIDs: 12032546, 20937277). [provided by RefSeq, Feb 2013]
Function
ATP binding; DNA binding; MDM2/MDM4 family protein binding; RNA polymerase II core promoter proximal region sequence-specific DNA binding transcription factor activity involved in positive regulation of transcription; RNA polymerase II core promoter seque
Synonyms
TP53; tumor protein p53; P53; BCC7; LFS1; TRP53; cellular tumor antigen p53; antigen NY-CO-13; tumor protein 53; phosphoprotein p53; p53 tumor suppressor; mutant tumor protein 53; transformation-related protein 53;
Citations
Have you cited CDBP2173 in a publication?
Let us know and earn a reward for your research.
| Product Name |
Cat. No. |
Applications |
Host Species |
Datasheet |
Price |
Add to Basket |
| Product Name |
Cat. No. |
Applications |
Host Species |
Datasheet |
Price |
Add to Basket |
Jeczen, R; Skomra, D; et al. P53/MDM2 overexpression in metastatic endometrial cancer: correlation with clinicopathological features and patient outcome. CLINICAL & EXPERIMENTAL METASTASIS 24:503-511(2007).
THORLACIUS, S; THORGILSSON, B; et al. TP53 MUTATIONS AND ABNORMAL P53 PROTEIN STAINING IN BREAST CARCINOMAS RELATED TO PROGNOSIS. EUROPEAN JOURNAL OF CANCER 31A:1856-1861(1995).
COA
Certificate of Analysis
 Antibody_1.gif)
